Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corvus PharmaceuticalsSTU:C17 -0.41%40 3-1 Month Momentum % is 27.03% as of Sep. 12, 2026. GuruFocus rates STU:C17 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Corvus Pharmaceuticals ranks better than 78.83% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-12), Corvus Pharmaceuticals's 3-1 Month Momentum % is 27.03%.
The industry rank for Corvus Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
STU:C17's 3-1 Month Momentum % is ranked better than 78.83% of 1384
companies
in the Biotechnology industry
Industry Median: 2.12
vs STU:C17: 27.03
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Corvus Pharmaceuticals 3-1 Month Momentum % Related Terms
STU:C17 vs APMD, SANA, ODTX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Corvus Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corvus Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals (STU:C17) has a 3-1 Month Momentum % of 27.03% as of Sep. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Corvus Pharmaceuticals and its competitors. According to the industry distribution chart, Corvus Pharmaceuticals ranks #293 out of 1384 companies in the Biotechnology industry, placing it in the top 21.2%.
Is Corvus Pharmaceuticals' 3-1 Month Momentum % too high?
Corvus Pharmaceuticals' current 3-1 Month Momentum % is 27.03%. The Biotechnology industry median 3-1 Month Momentum % is 2.12. Corvus Pharmaceuticals' value of 27.03% is 1175% above this industry median. Based on the distribution chart, Corvus Pharmaceuticals ranks #293 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corvus Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' 3-1 Month Momentum % compare to APMD and SANA?
According to the Biotechnology industry distribution chart, Corvus Pharmaceuticals ranks #293 out of 1384 companies for 3-1 Month Momentum %. This places Corvus Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 2.12. Corvus Pharmaceuticals' value of 27.03% is 1175% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 2.12, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corvus Pharmaceuticals's current 3-1 Month Momentum % of 27.03% is 1175% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Corvus Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corvus Pharmaceuticals's current 3-1 Month Momentum % is 27.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (STU:C17) has a current 3-1 Month Momentum % of 27.03%. The current 3-1 Month Momentum % is 27.03% and 1175% above the Biotechnology industry median of 2.12. Corvus Pharmaceuticals' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Corvus Pharmaceuticals (STU:C17), the current 3-1 Month Momentum % is 27.03% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
40GF Score
Get the complete analysis for STU:C17
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:C17 has been successfully added to your 
